659729-78-9

Basic information

• Product Name: 2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI)
• Synonyms: 2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI);3-AMINO-8-METHOXYQUINOXALIN-2(1H)-ONE;3-aMino-8-Methoxy-1,2-dihydroquinoxalin-2-one
• CAS NO: 659729-78-9
• Molecular Formula: C₉H₉N₃O₂
• Molecular Weight: 191.1867
• Product Categories: PIPERIDINE
• Mol File: 659729-78-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.476 g/cm³
• Refractive Index: 1.681
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI)(659729-78-9)
• EPA Substance Registry System: 2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI)(659729-78-9)

Safety Data

• Hazardous Substances Data: 659729-78-9(Hazardous Substances Data)

Usage

General Description

2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI) is a chemical compound with the molecular formula C10H10N2O2. It belongs to the class of quinoxalinone compounds, which are often used in medicinal and pharmaceutical research. The compound has a structure containing a quinoxaline ring with an amino group and a methoxy group attached to it. This chemical may have potential biological activities and pharmacological properties, making it a subject of interest for further study and development in the pharmaceutical industry. Its specific applications and uses may vary depending on the research and development of the compound.

InChI:InChI=1/C9H9N3O2/c1-14-6-4-2-3-5-7(6)12-9(13)8(10)11-5/h2-4H,1H3,(H2,10,11)(H,12,13)

Upstream product

• 83009-35-2 ethoxy-imino-acetic acid ethyl ester 
• 816-27-3 ethyl 2-ethoxy-2-iminoacetate 

Downstream Products

• 659729-80-3 3-amino-8-hydroxy-1H-quinoxalin-2-one 

Relevant articles and documents

Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate

A series of novel 4-oxopyrimidine TRPV1 antagonists was evaluated in assays measuring the blockade of capsaicin or acid-induced influx of calcium into CHO cells expressing TRPV1. The investigation of the structure-activity relationships in the heterocyclic A-region revealed the optimum pharmacophoric elements required for activity in this series and resulted in the identification of subnanomolar TRPV1 antagonists. The most potent of these antagonists were thoroughly profiled in pharmacokinetic assays. Optimization of the heterocyclic A-region led to the design and synthesis of 23, a compound that potently blocked multiple modes of TRPV1 activation. Compound 23 was shown to be effective in a rodent "on-target" biochemical challenge model (capsaicin-induced flinch, ED50 = 0.33 mg/kg p.o.) and was antihyperalgesic in a model of inflammatory pain (CFA-induced thermal hyperalgesia, MED = 0.83 mg/kg, p.o.). Based on its in vivo efficacy and pharmacokinetic profile, compound 23 (N-{4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-yl} -acetamide; AMG 517) was selected for further evaluation in human clinical trials.

Vanilloid receptor ligands and their use in treatments

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache,